Prime Medicine, Inc., o se kamupani na faʻavaeina e tuʻuina atu le folafolaga a le Palemia Faʻatonutonu, o le aso na folafolaina ai le faʻaopopoina o agavaʻa i lona tulaga faʻavae i luga o talu ai nei saienitisi suʻesuʻega.

"Matou te matua fiafia lava e vaʻavaʻai faʻaleleia ua alualu i luma o le a faʻateleina atili ai le aoga a le Palemia Editing o se togafitiga," o le tala lea a Keith Gottesdiener, MD, CEO o le Palemia Faʻafomaʻi. "O nei alualu i luma, i le pito i luga o le maeʻa eleele faʻavae tekonolosi, e foliga mai e faʻateleina ai le aoga o le Palemia Faʻatonutonu, ma o le a faʻalauteleina ia eria e galue ai le Palemia, atonu e faʻalauteleina ai le tatou aʻapa atu i faʻamaʻi faʻaopoopo e leʻi mafai ona faʻataʻitaʻi e se e talanoa ai. ”

Faatasi ai ma nei alualu i luma fou faia e fafo saienitisi, ma faatasi ai ma Palemia Faʻagasologa o taumafaiga faifai pea e lona lotoifale atinae 'au, o loʻo faʻamoemoe le kamupani e faʻaleleia atili le faʻalelei o le Palemia Editing, agavaʻa, ma lelei. O agavaʻa o loʻo faʻamatalaina i ni pepa talu ai nei i le Natura Biotechnology ma le Cell e mafai ai ona fausia ni togafitiga faʻalelei e ala i le faʻaleleia atili o gaioiga faʻatonutonu.

O le tasi muamua e aofia ai le faʻalelei le Palemia Faʻatonutonu taiala RNA (pegRNA). O le Prime Editing e faʻaaogaina ai le molemeni o le pegRNA e saili ai le faʻatulagaina o le kenera ma faʻatonutonu ai le manaʻoga e toe faʻaleleia pe toe teuteuina. I se pepa na lomia faasalalau i le Natura Biotechnology ia Oketopa 4, 2021, o tusitala na taʻitaʻia e David R. Liu, o se tasi na amataina e le Fomaʻi Faʻafomaʻi, na faʻaalia o le lelei, faʻatinoina o pegRNAs (epegRNAs) e mafai ona faʻaleleia atili ai le aoga o le faʻatonutonuina o ni gaioiga.

O loʻo tuliloaina foʻi e le kamupani faʻamatalaga talu ai nei mo le faʻaleleia atili o le lelei e ala i le faʻataʻitaʻia o se auala e toe faʻaleleia ai le DNA. I se pepa lolomiina i Cell i Oketopa 14, 2021, tusitala taʻitaʻia e Liu ma Britt Adamson faʻailoa mai se faʻapitoa DNA toe faʻaleleia auala, valaʻauina le mismatch toe faʻaleleia auala, lea e faʻamalosia malosiaga sili lelei faʻatonutonuina lelei. Na latou faʻaalia o le faʻatonutonu gaioiga mafai ona faʻateleina tele-lafu, ma le manaʻomia e-oloa mafai ona faʻaititia tele-lafu, e ala i le faʻavasegaina o le le fetaui lelei auala faʻaleleia auala e tele auala.

O le Palemia Faʻafomaʻi o loʻo taofia aia tatau faʻapisinisi mai le Broad Institute of MIT ma Harvard e faʻaaoga ai le Prime Editing mo togafitiga o le tagata, aʻo saienitisi ma kamupani i le lalolagi atoa o loʻo faʻaaoga pea le Prime Editing mo suʻesuʻega ma isi faʻaoga.

OA MEA E AVEA MAI LENEI TUSI:

“These advancements, on top of an already groundbreaking foundational technology, are likely to increase the efficiency of Prime Editing, and will broaden the areas where Prime Editing might work, potentially extending our reach to additional diseases that no gene editing approach has yet been able to address.
O le Palemia Faʻafomaʻi o loʻo taofia aia tatau faʻapisinisi mai le Broad Institute of MIT ma Harvard e faʻaaoga ai le Prime Editing mo togafitiga o le tagata, aʻo saienitisi ma kamupani i le lalolagi atoa o loʻo faʻaaoga pea le Prime Editing mo suʻesuʻega ma isi faʻaoga.
Prime Editing uses a pegRNA molecule to find the gene target and to direct the desired repair or edit.